|
|
Sigilon Therapeutics Inc (SGTX) |
|
Price: $22.4700
$-0.59 
-2.559%
|
| Day's High:
| $23.1
| Week Perf:
| 3.98 %
|
| Day's Low: |
$ 22.09 |
30 Day Perf: |
4.27 % |
| Volume (M): |
84 |
52 Wk High: |
$ 28.00 |
| Volume (M$): |
$ 1,878 |
52 Wk Avg: |
$4.09 |
| Open: |
$22.90 |
52 Wk Low: |
$0.29 |
|
|
| Market Capitalization (Millions $) |
56 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
18 |
| Net Income (TTM) (Millions $) |
-30 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
1 |
Sigilon Therapeutics Inc
Company Address: 100 Binney Street, Suite 600 Cambridge 2142 MA
Company Phone Number: 336-7540 Stock Exchange / Ticker: NASDAQ SGTX
| SGTX is expected to report next financial results on November 09, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Renovaro Biosciences Inc
Renovaro Biosciences Inc, a major pharmaceutical preparations company, has released its financial report for the fiscal period ending June 30, 2023. During this period, the company experienced zero gain per share, an improvement compared to the same period a year ago when it reported a gain of $0.33 per share. It also represents an increase from the preceding financial reporting period when the company reported a loss of $0.08 per share.
In terms of revenue, Renovaro Biosciences Inc did not experience any change compared to the corresponding financial reporting period a year ago. The revenue remained at $0.00 million, and there was no sequential change either. This stability in revenue could be an area of concern for the company, as it suggests a lack of growth or expansion in its operations.
|
|
Immuron Limited
In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.
|
|
Procyon Corporation
Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.
|
|
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.
|
|
Palatin Technologies Inc
Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
|
| Per Share |
Current |
| Earnings (TTM) |
-3.7 $ |
| Revenues (TTM) |
7.06 $
|
| Cash Flow (TTM) |
- |
| Cash |
13.95 $
|
| Book Value |
10.97 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.7 $
|
| Revenues (TTM) |
7.06 $ |
| Cash Flow (TTM) |
- |
| Cash |
13.95 $
|
| Book Value |
10.97 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
